Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 04, 2019 09:59 ET | Source: AC Immune SA

AC Immune to Report Progress of Early-Stage Pipeline at AD/PD™ Congress

LAUSANNE, Switzerland, March 04, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
February 20, 2019 07:00 ET | Source: AC Immune SA

AC Immune Announces Anti-Tau Monoclonal Antibody Entering Second Phase 2 Trial in Moderate Alzheimer’s Disease

Study complements ongoing trial in the prodromal to mild population LAUSANNE, Switzerland, Feb. 20, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage...
February 07, 2019 07:00 ET | Source: AC Immune SA

AC Immune Makes Two Appointments to Executive Committee to Accelerate Product Development

LAUSANNE, Switzerland, Feb. 07, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
January 30, 2019 01:00 ET | Source: AC Immune SA

AC Immune Reports Discontinuation of Phase III CREAD 1 and 2 Studies of Crenezumab in Alzheimer’s Disease

Decision follows Independent Data Monitoring Committee analysisThe Alzheimer’s Prevention Initiative (API) study of crenezumab in familial Alzheimer’s disease continuesThe Phase II anti-tau TAURIEL...
January 03, 2019 04:00 ET | Source: AC Immune SA

AC Immune Announces Appointment of Dr. Marie Kosco-Vilbois as Chief Scientific Officer

Lausanne, Switzerland, January 3, 2019 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on Neurodegenerative Diseases, today...
December 19, 2018 06:30 ET | Source: AC Immune SA

AC Immune and WuXi Biologics to Establish an Exclusive Strategic Partnership

AC Immune to draw on WuXi Biologics' expertise in manufacturing innovative New Biological Entities against CNS disorders including proprietary WuXiUP continuous manufacturing platform that can...
December 12, 2018 06:30 ET | Source: AC Immune SA

AC Immune and Lilly Announce License and Collaboration Agreement

Multi-year agreement focuses on Morphomer tau aggregation inhibitors, for the potential treatment of Alzheimer's disease and other neurodegenerative diseases. AC Immune to receive an initial...
December 07, 2018 16:15 ET | Source: AC Immune SA

In Memoriam: Dr. Andreas Muhs CSO, Scientific Leader and Friend has Passed Away

Lausanne, Switzerland, December 7, 2018 - AC Immune SA (NASDAQ: ACIU), announced today that its Chief Scientific Officer, Dr. Andreas Muhs, passed away following a period of illness. "It is with...
November 15, 2018 04:00 ET | Source: AC Immune SA

AC Immune Awarded Third Follow-up Grant from The Michael J. Fox Foundation for First-in-Human Study of a Positron Emission Tomography (PET) Tracer for Parkinson's Disease

Grant supports next step in development of potentially first alpha-synuclein PET tracer for Parkinson's diseaseStart of first-in-human study of current lead is scheduled for Q1 2019Follow-up...
November 13, 2018 04:00 ET | Source: AC Immune SA

AC Immune Reports Third Quarter 2018 Financial Results and Corporate Update

Announced important clinical milestones for ACI-24 vaccine in Alzheimer's disease and Down Syndrome Company record high, period end cash position of approximately CHF 200 million that is...